Open Orphan plc (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, has today announced, further to its announcement of 13 February 2020, the appointment to the board of Leo Toole as Chief Financial Officer.
Leo Toole brings over 20 years’ experience in senior finance roles in Pharmaceuticals, Medical Technology and FMCG sectors. He has held senior finance positions at Procter and Gamble, ResMed and Sublimity Therapeutics. Through positions in multinational companies across Europe and in the venture capital space in the UK and Ireland, he has extensive experience in building finance teams, corporate development, equity and debt financing, public markets, and mergers and acquisitions. Leo is a Business graduate of Trinity College Dublin, Ireland and HEC Liège, Belgium. He also holds an MBA with Distinction from INSEAD in France and Singapore.
Cathal Friel, Executive Chairman of Open Orphan commented:
“We are delighted to welcome Leo Toole to the board following the successful completion of his regulatory due diligence checks. Leo brings with him a wealth of experience which will be invaluable to us at what is an exciting time for Open Orphan as we steer the company to profitability in the coming months and increasing deal flow and revenue in the year ahead, he is a great addition to the board. These are exciting times for Open Orphan because following the acquisition of hVIVO we are now the world leader in the provision of viral challenge study models and, as such, we are ideally positioned to provide assistance and help to vaccine manufacturers and governments around the world to successfully deal with and in the search for solutions to the Coronavirus outbreak.”
Leo Toole does not hold any shares or options in the Company.